[Federal Register Volume 85, Number 123 (Thursday, June 25, 2020)] [Notices] [Page 38147] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2020-13656] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing Michael Shmilovich, [email protected], the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: Technology description follows. Liposome Nanodecoys That Protect Against SARS-COV-2 Available for licensing and commercial development are patent rights covering a liposomal vesicle (a ``nanodecoy'') with a lipid bilayer with one or more proteins recognized by a pathogen (e.g., SARS- CoV-2) and one or more cytokine receptors (such as IL-6; receptors: CD126, CD130; IL-1; receptors: CD121a, CD121b, IL-8; receptors: IL-8RB; IL-12; receptors: CD212; TNF-[alpha]; receptors: CD120a, CD120b; IFN- [gamma]; receptors: CD119, IFN-[alpha]/[beta]; receptors: CD118) and wherein the liposomal vesicle is non-replicating. Nanodecoys that display angiotensin-converting enzyme 2 (ACE2) and multiple cytokine receptors, are able to sequester SARS-CoV-2 and inhibit viral replication and infection, as well as to mitigate COVID-19-induced cytokine release syndrome (CRS) in susceptible cells. Potential Commercial Applications:COVID-19 SARS-CoV-2 Cytokine release syndrome [cir] immunosuppression Viral inhibition [cir] Receptor binding competition Development Stage: Preclinical Inventors: Xiaoyuan (Shawn) Chen (NIBIB) and Lang Rao (NIBIB). Intellectual Property: HHS Reference No. E-144-2020-0-US-01 ``Engineered Cell Membrane Nanodecoys To Protect Against COVID-19;'' U.S. Provisional Patent Application 63/038,380 filed June 12, 2020. Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; [email protected]. Dated: June 17, 2020. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2020-13656 Filed 6-24-20; 8:45 am] BILLING CODE 4140-01-P